Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Hyperliquid Strategies Inc (PURR : NSDQ)

• Company Description    Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. Hyperliquid Strategies Inc, formerly known as Sonnet BioTherapeutics Holdings Inc., is based in NEW YORK. Number of Employees: 9

• Price / Volume Information    Yesterday's Closing Price: $3.56 Daily Weekly Monthly 20 Day Moving Average: 1,130,495 shares Shares Outstanding: 127.03 (millions) Market Capitalization: $452.21 (millions) Beta: 1.51 52 Week High: $4.65 52 Week Low: $3.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.11% -0.94% 12 Week -24.82% -26.03% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 100 OVERLOOK CENTER SUITE 102 - PRINCETON,NJ 08540 USA ph: 609-375-2227 fax: 704-366-2463 info@sonnetbio.com http://www.sonnetbio.com

• General Corporate Information    Officers Raghu Rao - Chief Executive Officer and Director Donald Griffith - Chief Financial Officer and Director Albert Dyrness - Director Nailesh Bhatt - Director Donald Griffith - Director Peer Information Hyperliquid Strategies Inc (EIIN) Hyperliquid Strategies Inc (AFMI) Hyperliquid Strategies Inc (DRL) Hyperliquid Strategies Inc (GRFPY) Hyperliquid Strategies Inc (IGOT) Hyperliquid Strategies Inc (ATLC) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: FIN-MISC SVCS Sector: Finance CUSIP: 44916Y106 SIC: 2834 Fiscal Year Fiscal Year End: September Last Reported Quarter: 06/01/25 Next Expected EPS Date: 02/12/26 Share - Related Items Shares Outstanding: 127.03 Most Recent Split Date: 9.00 (0.13:1) Beta: 1.51 Market Capitalization: $452.21 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.40 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/12/26

• Fundamental Ratios P/E Current FY Estimate: 8.90 Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.34 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 83.04% vs. Previous Quarter: -6.74% Sales Growth vs. Year Ago Period: 5,163.16% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -514.78 06/30/25 - -4,646.10 ROA 12/31/25 - - 09/30/25 - -229.07 06/30/25 - -342.21 Current Ratio 12/31/25 - - 09/30/25 - 3.50 06/30/25 - 0.26 Quick Ratio 12/31/25 - - 09/30/25 - 3.50 06/30/25 - 0.26 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - -1,579.30 06/30/25 - -1,339.60 Book Value 12/31/25 - - 09/30/25 - 1.52 06/30/25 - -0.91 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - - Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - -

Powered by Zacks Investment Research ©